BioNTech SE (BNTX) Tops Q3 EPS, Warns on COVID Revenue

BioNTech SE (NASDAQ: BNTX) reported Q3 EPS of EUR0.67, EUR0.05 better than the analyst estimate of EUR0.62. Revenue for the quarter came in at EUR895.3 million versus the consensus estimate of EUR837.61 million.

GUIDANCE:

Updated 2023 COVID-19 vaccine revenue guidance of around EUR4 billion, versus EUR5 billion prior.

For earnings history and earnings-related data on BioNTech SE (BNTX) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• Morgan Stanley Resumes Global Payments (GPN) at Equalweight